Evidence map›Paper›PMID 33810240›Full record

ArticleMolecules (Basel, Switzerland)2021

Methiothepin Increases Chemotherapy Efficacy against Resistant Melanoma Cells.

Nelly Durand, Méliné Simsir, Laurie Signetti, Fabien Labbal, Robert Ballotti, Isabelle Mus-Veteau

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Adriamycin-loaded exosome with anti-CD20 aptamers selectively suppresses human CD20+ melanoma stem cells.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2023
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Nelly DurandUniversité Côte d'Azur, CNRS, IPMC, France, Institut de Pharmacologie Moléculaire et Cellulaire, 660 route des Lucioles, 06560 Valbonne, France.
Méliné SimsirUniversité Côte d'Azur, CNRS, IPMC, France, Institut de Pharmacologie Moléculaire et Cellulaire, 660 route des Lucioles, 06560 Valbonne, France.
Laurie SignettiUniversité Côte d'Azur, CNRS, IPMC, France, Institut de Pharmacologie Moléculaire et Cellulaire, 660 route des Lucioles, 06560 Valbonne, France.
Fabien LabbalUniversité Côte d'Azur, CNRS, IPMC, France, Institut de Pharmacologie Moléculaire et Cellulaire, 660 route des Lucioles, 06560 Valbonne, France.
Robert BallottiUniversité Côte d'Azur, INSERM, Equipe Labellisée ARC, 2019, C3M, Bâtiment Universitaire Archimed 151 Route Saint Antoine de Ginestière BP 2 3194, CEDEX 3, 06204 Nice, France.ORCID 0000-0002-7322-4908
Isabelle Mus-VeteauUniversité Côte d'Azur, CNRS, IPMC, France, Institut de Pharmacologie Moléculaire et Cellulaire, 660 route des Lucioles, 06560 Valbonne, France.ORCID 0000-0001-5739-7684
Centre National de la Recherche Scientifique · FRInserm · FR

Funding

Agence Nationale de la Recherche ANR-15-IDEX-01Association France Cancer 2017-2020Région PACA APRF program (2013-17362)
6 · The paper itself

Abstract

We previously reported that methiothepin, a small molecule known as a nonselective serotonin 5-HT receptor antagonist, inhibited the doxorubicin efflux activity of the Hedgehog receptor Ptch1 and enhanced the cytotoxic, pro-apoptotic, anti-proliferative, and anti-clonogenic effects of doxorubicin on adrenocortical carcinoma cells. Here, we show that methiothepin also inhibits doxorubicin efflux and increases doxorubicin cytotoxicity in melanoma cells which endogenously overexpress Ptch1. Melanoma patients having the BRAF

Indexed as

Antineoplastic AgentsMethiothepinCell Line, TumorCell ProliferationDoxorubicinDrug Resistance, NeoplasmHumansMelanomaPatched-1 ReceptorPyridonesPyrimidinonesSkin NeoplasmsVemurafenibAntineoplastic AgentsDoxorubicinMethiothepinPatched-1 ReceptorPTCH1 protein, humanPyridonesPyrimidinonestrametinibVemurafenibchemotherapy resistancemelanomamethiothepinPtch1Ptch1 drug efflux inhibitortrametinibvemurafenib

Identifiers

PMID33810240
PMCPMC8037503
OpenAlexW3137504083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.